A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

Recruiting

Phase 3

Vicadrostat & EmpagliflozinA Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

Sponsor:

Boehringer Ingelheim

Code:

NCT07064473

Conditions

Diabetes Mellitus, Type 2

Hypertension

Cardiovascular Diseases

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Vicadrostat

Empagliflozin

Placebo matching Vicadrostat

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-26. This information was provided to ClinicalTrials.gov by Boehringer Ingelheim on 2025-11-12.